Loading clinical trials...
Loading clinical trials...
A Phase II, Multicentre, Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients With BRCA Mutations and Early Stage HER2-Negative Breast Cancer
Conditions
Interventions
Neoadjuvant Olaparib monotherapy group
Neoadjuvant combination therapy with olaparib plus durvalumab
Locations
37
United States
Research Site
Greeley, Colorado, United States
Research Site
Loveland, Colorado, United States
Research Site
Boston, Massachusetts, United States
Research Site
Portland, Oregon, United States
Research Site
Philadelphia, Pennsylvania, United States
Research Site
Melbourne, Australia
Start Date
November 7, 2022
Primary Completion Date
November 20, 2024
Completion Date
December 31, 2026
Last Updated
June 10, 2025
NCT04541381
NCT05468034
NCT03137095
NCT07547774
NCT06393374
NCT04852887
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions